← All trials
NCT05245838
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 10, 2022
- Primary completion
- Oct 20, 2022
- Completion date
- Oct 20, 2022
- First posted
- Feb 18, 2022
- Last posted
- Nov 7, 2022
- Enrollment
- 150
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Dynavax Technologies CorporationLead sponsor
- Dynavax Technologies CorporationStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.